Effects of adjunct treatment with intravenous Octagam on the course of severe COVID-19: results from a retrospective cohort study.

Conclusion: Clinically relevant benefits through adjunct Octagam treatment in COVID-19 need to be confirmed in a randomized, controlled trial. PMID: 33236646 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research